1637254-93-3

Basic information

• Product Name: Afatinib IMpurity I
• Synonyms: Afatinib IMpurity I
• CAS NO: 1637254-93-3
• Molecular Formula: C22H19BrClFN4O3
• Molecular Weight: 521.77
• Mol File: 1637254-93-3.mol

Chemical Properties

• Boiling Point: 697.7±55.0 °C(Predicted)
• Appearance: /
• Density: 1.605±0.06 g/cm3(Predicted)
• PKA: 11.15±0.43(Predicted)
• CAS DataBase Reference: Afatinib IMpurity I(CAS DataBase Reference)
• NIST Chemistry Reference: Afatinib IMpurity I(1637254-93-3)
• EPA Substance Registry System: Afatinib IMpurity I(1637254-93-3)

Safety Data

• Hazardous Substances Data: 1637254-93-3(Hazardous Substances Data)

Upstream product

• 314771-88-5 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazoline 
• 314771-76-1 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazoline 
• 51544-74-2 4-bromocrotonic acid chloride 
• 162012-69-3 7-fluoro-6-nitro-4-hydroxyquinazoline 
• 162012-70-6 4-chloro-7-fluoro-6-nitroquinazoline 
• 162012-69-3 7-fluoro-6-nitro-3H-quinazolin-4-one 
• 162012-67-1 N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine 
• 99083-25-7 4-bromocrotonyl chloride 

Downstream Products

• 1680184-59-1 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrothran-3-yl)oxy]quinazoline 

Relevant articles and documents

Minimalist linkers suitable for irreversible inhibitors in simultaneous proteome profiling, live-cell imaging and drug screening

Activity-based protein profiling (ABPP) and bioimaging have been powerful approaches for in situ drug screening and target identification. However, these approaches are still hindered by the preparation of high-quality probes. To address this challenge, we developed a series of novel minimalist linkers for irreversible inhibitors by incorporation of various bioorthogonal handles into an α,β-unsaturated amide, a common moiety of many irreversible inhibitors. The linker-containing probes have been demonstrated to be suitable for simultaneous protein labelling, live cell imaging and drug screening.

Synthesis method of afatinib

The invention discloses a synthesis method of afatinib. The synthesis method comprises the steps as follows: (a), a compound shown in a formula (4) reacts with a compound shown in a formula (5) to produce a compound shown in a formula (3); (b), the compound shown in the formula (3) produces a compound shown in a formula (2) in an organic solvent under the action of a bromination reagent; (c) the compound shown in the formula (2) reacts with dimethylamine to produce a compound shown in a formula (1). The synthesis reaction of the route is suitable for mass production, double bond cis-trans isomerism is not involved, and the product purity is very high. The reaction route is shown in the description.

4 - (Substituted phenylamino) aminoquin oxazolines, preparation method and application thereof

The invention specifically relates to novel 4-(substituted phenylamino)quinazoline compounds with antineoplastic activity and a preparation method thereof, belonging to the field of pharmaceutical chemical engineering. The 4-(substituted phenylamino)quinazoline compounds have an effective irreversible inhibiting effect on tyrosine kinase and/or good in-vivo pharmacokinetic behavior and are an effective tyrosine kinase irreversible inhibitor.

Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors

We have developed a series of 6, 7-disubstituted-4-(arylamino) quinazoline derivatives that functioned as irreversible EGFR inhibitors, and these compounds exhibited excellent enzyme inhibition potency. As compared with afatinib, some of them showed significantly enhanced activities towards H1975 cells (EGFR-T790M). Furthermore, the optimized compounds 7q and 8f also demonstrated good pharmacokinetic profiles, oral bioavailability as well as excellent in vivo efficacy in H1975 and HCC827 xenografts at a non-toxic dose. Based on the improved safety and efficacy against EGFR-T790M resistance, 7q and 8f are promising candidates for further studies.

Aminoquinazoline Derivative And Use Thereof In Preparing Anti-Malignant Tumor Medicament

The invention discloses a new amino-quinazoline derivative and its use in preparing drugs for preventing and/or treating malignancies. The amino-quinazoline derivative of the invention is an ideal, high effective, dual and irreversible EGFR and HER2 kinas

QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS

Disclosed herein are protein kinase inhibitors, more particularly novel quinazoline derivatives and pharmaceutical compositions thereof,and method of use thereof.

AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF

Provided herein are aminoquinazoline compounds, salts and uses thereof. The compounds have Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug ther